Skip to main content

Solexa Secures $75M Equity Financing Commitment; Cash Will Help Roll Out GAS Sequencer

NEW YORK (GenomeWeb News) – Solexa has secured a committment to sell $75 million in common stock Azimuth Opportunity, the company said today.
 
Solexa said it plans to use the cash to develop and commercialize its Genome Analysis System, for working capital, and for other general corporate purposes.
 
The commitment is for two years. During the term, Solexa may sell registered shares of its common stock to Azimuth at a small discount to the market price. The timing and amount of sales will be at Solexa’s discretion, the company said.
 
Solexa shipped its first 1G Genome Analyzers to two early-access customers in late June and has said in the past that it wants to launch the instrument widely by the end of this year.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.